UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
10.08
-0.63 (-5.88%)
At close: Feb 21, 2025, 4:00 PM
10.27
+0.19 (1.86%)
After-hours: Feb 21, 2025, 5:54 PM EST
UroGen Pharma Revenue
UroGen Pharma had revenue of $25.20M in the quarter ending September 30, 2024, with 20.87% growth. This brings the company's revenue in the last twelve months to $89.36M, up 15.64% year-over-year. In the year 2023, UroGen Pharma had annual revenue of $82.71M with 28.52% growth.
Revenue (ttm)
$89.36M
Revenue Growth
+15.64%
P/S Ratio
4.22
Revenue / Employee
$444,592
Employees
201
Market Cap
425.37M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 82.71M | 18.36M | 28.52% |
| Dec 31, 2022 | 64.36M | 16.32M | 33.96% |
| Dec 31, 2021 | 48.04M | 36.24M | 307.17% |
| Dec 31, 2020 | 11.80M | 11.78M | 65,450.00% |
| Dec 31, 2019 | 18.00K | -1.11M | -98.40% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
URGN News
- 2 days ago - UroGen Advances Long-Term Growth Strategy by Acquiring a Next-Generation Investigational Oncolytic Virus (ICVB-1042) and Announces Multiple Strategic Research Collaborations - Business Wire
- 8 days ago - UroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102 - Business Wire
- 10 days ago - Data from a Long-Term Follow-up Study to the OLYMPUS Trial that Shows a Median Duration of Response of Nearly Four Years in Patients Achieving Complete Response with JELMYTO Published in The Journal of Urology - Business Wire
- 22 days ago - UroGen: Upcoming PDUFA, Some Concerns Remain - Seeking Alpha
- 23 days ago - UroGen Pharma to Present at Upcoming Investor Conferences - Business Wire
- 4 weeks ago - New Real-World Durability of Response Data for JELMYTO Reports 68% Recurrence-Free Survival Rate (RFS) at Three Years Across a Broad Patient Population with Low-Grade Upper Tract Urothelial Cancer (LG-UTUC) - Business Wire
- 5 weeks ago - ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025 - Business Wire
- 2 months ago - UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire